表紙
市場調查報告書

關注市場分析:痤瘡

Market Spotlight: Acne

出版商 Datamonitor Healthcare 商品編碼 594578
出版日期 內容資訊 英文 53 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:痤瘡 Market Spotlight: Acne
出版日期: 2019年11月27日內容資訊: 英文 53 Pages
簡介

本報告提供痤瘡的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等調查。

分析的要點

疾病的背景情況

治療方法

  • 局部治療
  • 全身治療
  • 物理治療

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

將產生的主要事件

法規相關的主要事件 (共2件)

授權合約、資產收購交易 (1件)

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位
  • 主要企業的主要趨勢 (共2件)

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0181187

This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 624 million prevalent cases of acne worldwide, and forecasts that number to increase to 683 million prevalent cases by

2026. Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.

The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with two drugs in the NDA/BLA phase.

Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.

High-impact upcoming events for drugs in the acne space comprise topline Phase II trial results for FCD105, topline Phase III trial results for TWIN, and estimated PDUFA dates for Arazlo and Winlevi/Breezula.

The overall likelihood of approval of a Phase I dermatology-general asset is 24.7%, and the average probability a drug advances from Phase III is 75.8%. Drugs, on average, take 7.8 years from Phase I to approval, compared to 7.7 years in the overall dermatology space.

There have been 21 licensing and asset acquisition deals involving acne drugs during 2014-19. The largest deal was the $650m agreement in 2018 between Almirall and Allergan for the acquisition of a portfolio of five products from Allergan's Medical Dermatology unit in the US, which comprises of mature and growth brands Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide), and Seysara (sarecycline).

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III-IV, and 48% in Phase I-II.

The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.

GlaxoSmithKline leads industry sponsors with by far the highest number of clinical trials for acne, followed by Allergan.

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

9 TREATMENT

9 Topical therapy

9 Systemic therapy

10 Physical treatments

11 EPIDEMIOLOGY

14 MARKETED DRUGS

18 PIPELINE DRUGS

26 RECENT EVENTS AND ANALYST OPINION

26 ANT-1207 for Acne (June 25, 2019)

27 VB 1953 for Acne (May 13, 2019)

28 VB 1953 for Acne (May 13, 2019)

30 Winlevi / Breezula for Acne (March 26, 2019)

32 Aklief for Acne (February 22, 2019)

34 Amzeeq for Acne (September 11, 2018)

36 Winlevi / Breezula for Acne (July 10, 2018)

39 KEY UPCOMING EVENTS

40 KEY REGULATORY EVENTS

40 Foamix Earns First Approval For Topical Minocycline With Amzeeq

40 FDA Approves Aklief Cream for Acne Treatment

40 Cassiopea Submits Acne Drug With New Mechanism Of Action

40 Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions

41 Foamix Submits First Topical Minocycline For Acne

42 PROBABILITY OF SUCCESS

43 LICENSING AND ASSET ACQUISITION DEALS

44 PARENT PATENTS

45 REVENUE OPPORTUNITY

46 CLINICAL TRIAL LANDSCAPE

47 Sponsors by status

48 Sponsors by phase

50 BIBLIOGRAPHY

50 Prescription information

52 APPENDIX

LIST OF FIGURES

  • 13 Figure 1: Trends in prevalent cases of acne, 2017-26
  • 18 Figure 2: Overview of pipeline drugs for acne in the US
  • 19 Figure 3: Pipeline drugs for acne, by company
  • 19 Figure 4: Pipeline drugs for acne, by drug type
  • 20 Figure 5: Pipeline drugs for acne, by classification
  • 28 Figure 6: VB 1953 for Acne (May 13, 2019): Phase II - Proof-of-Concept (ex. US)
  • 30 Figure 7: VB 1953 for Acne (May 13, 2019): Phase I - First-In-Human
  • 32 Figure 8: Winlevi / Breezula for Acne (March 26, 2019): Phase III - CB-03-01/27 (Long-Term Extension)
  • 34 Figure 9: Aklief for Acne (February 22, 2019): Phase III - Perfect 1, Phase III - Perfect 2
  • 36 Figure 10: Amzeeq for Acne (September 11, 2018): Phase III - FX2017-22
  • 38 Figure 11: Winlevi / Breezula for Acne (July 10, 2018): Phase III - CB-03-01/25, Phase III - CB-03-01/26
  • 39 Figure 12: Key upcoming events in acne
  • 42 Figure 13: Probability of success in the acne pipeline
  • 43 Figure 14: Licensing and asset acquisition deals in acne, 2014-19
  • 44 Figure 15: Parent patents in acne
  • 46 Figure 16: Clinical trials in acne
  • 46 Figure 17: Top 10 drugs for clinical trials in acne
  • 47 Figure 18: Top 10 companies for clinical trials in acne
  • 47 Figure 19: Trial locations in acne
  • 48 Figure 20: Acne trials status
  • 49 Figure 21: Acne trials sponsors, by phase

LIST OF TABLES

  • 12 Table 1: Prevalent cases of acne, 2017-26
  • 15 Table 2: Marketed drugs for acne
  • 21 Table 3: Pipeline drugs for acne in the US
  • 26 Table 4: ANT-1207 for Acne (June 25, 2019)
  • 27 Table 5: VB 1953 for Acne (May 13, 2019)
  • 29 Table 6: VB 1953 for Acne (May 13, 2019)
  • 31 Table 7: Winlevi / Breezula for Acne (March 26, 2019)
  • 32 Table 8: Aklief for Acne (February 22, 2019)
  • 35 Table 9: Amzeeq for Acne (September 11, 2018)
  • 36 Table 10: Winlevi / Breezula for Acne (July 10, 2018)
  • 45 Table 11: Historical global sales, by drug ($m), 2014-18
  • 45 Table 12: Forecasted global sales, by drug ($m), 2019-23
Back to Top